支气管舒张、运动训练与行为干预对慢阻肺症状和体力活动的影响
本研究为12周随机、部分双盲、安慰剂对照平行组试验,纳入慢阻肺患者并全部进入自我管理行为修正(SMBM)项目,比较安慰剂、噻托溴铵、噻托溴铵/奥达特罗及联合8周运动训练对运动耐力和体力活动的影响。结果显示含噻托溴铵/奥达特罗方案显著改善第8周耐力穿梭步行试验时间,但未在SMBM基础上进一步增加客观体力活动,仅减少活动相关呼吸困难与困难。
要点
- 在SMBM基础上,噻托溴铵/奥达特罗联合或不联合运动训练均显著改善第8周运动耐力时间。
- 联合支气管舒张未较单用SMBM进一步增加第12周每日步数。
- 含噻托溴铵/奥达特罗方案减少活动相关呼吸困难,联合运动训练还减少活动相关困难。
核心结论
- 在参与SMBM项目的慢阻肺患者中,噻托溴铵/奥达特罗联合或不联合运动训练均改善运动耐力时间。
- 联合支气管舒张联合或不联合运动训练未较单用SMBM进一步增加客观体力活动,但减少活动相关呼吸困难与困难。
研究设计与样本
- 12周随机、部分双盲、安慰剂对照、平行组试验(PHYSACTO;NCT02085161)。
- 所有患者进入SMBM并按1:1:1:1随机至每日一次安慰剂、噻托溴铵5 μg、噻托溴铵/奥达特罗5/5 μg、或噻托溴铵/奥达特罗5/5 μg联合8周运动训练。
- 主要终点为第8周耐力穿梭步行试验测定的运动耐力时间。
主要发现
- 第8周运动耐力时间较SMBM联合安慰剂显著改善:联合运动训练治疗比1.46(95%CI 1.20-1.78;P=0.0002),未联合运动训练治疗比1.29(95%CI 1.06-1.57;P=0.0109)。
- 第12周每日步数较基线在SMBM联合安慰剂增加1,098步,加用其他治疗未观察到显著进一步增加。
- 在SMBM基础上加用噻托溴铵/奥达特罗联合或不联合运动训练较安慰剂减少活动相关呼吸困难。
- 在SMBM基础上加用噻托溴铵/奥达特罗联合运动训练较安慰剂减少活动相关困难。
临床怎么用
- 对参与自我管理行为修正项目的慢阻肺患者,可考虑噻托溴铵/奥达特罗联合或不联合运动训练以改善运动耐力。
- 若目标是增加每日客观体力活动,单纯联合支气管舒张联合或不联合运动训练在SMBM基础上未显示额外获益。
- 含噻托溴铵/奥达特罗方案可用于减少活动相关呼吸困难,联合运动训练还可减少活动相关困难。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: Bronchodilation and exercise training (ExT) improve exercise tolerance in patients with chronic obstructive pulmonary disease (COPD); however, behavior modification is required to impact daily physical activity (PA). OBJECTIVES: To assess whether tiotropium/olodaterol, with or without ExT, would improve exercise endurance time (EET) and PA compared with placebo in patients participating in a self-management behavior-modification (SMBM) program. METHODS: This was a 12-week, randomized, partially double-blind, placebo-controlled, parallel-group trial in patients with COPD (PHYSACTO; NCT02085161). All patients were enrolled into SMBM and randomized 1:1:1:1 to once-daily placebo, tiotropium 5 μg, tiotropium/olodaterol 5/5 μg, or tiotropium/olodaterol 5/5 μg plus 8 weeks ExT. EET, measured by endurance shuttle walk test after 8 weeks, was the primary endpoint. Additional endpoints assessed downstream effects on PA (measured via accelerometry), and activity-related dyspnea and difficulty (using validated patient-reported questionnaires). MEASUREMENTS AND MAIN RESULTS: SMBM plus tiotropium/olodaterol, with or without ExT, significantly improved EET at Week 8 versus SMBM plus placebo (treatment ratio vs. placebo: with ExT, 1.46; 95% confidence interval, 1.20-1.78; P = 0.0002; without ExT, 1.29; 95% confidence interval, 1.06-1.57; P = 0.0109). No significant increases in steps per day from baseline were observed over SMBM plus placebo at Week 12 (increase of 1,098) when other therapies were added. Adding tiotropium/olodaterol, with or without ExT, to SMBM reduced activity-related dyspnea versus placebo, whereas adding tiotropium/olodaterol plus ExT reduced activity-related difficulty. CONCLUSIONS: Tiotropium/olodaterol, with or without ExT, improved EET in patients with COPD taking part in an SMBM program. Combination bronchodilation, with or without ExT, did not provide additional increases in objective PA compared with SMBM alone but did reduce PA-related dyspnea and difficulty. Clinical trial registered with www.clinicaltrials.gov (NCT02085161).
引用
- Troosters T, Maltais F, Leidy N, et al. Effect of Bronchodilation, Exercise Training, and Behavior Modification on Symptoms and Physical Activity in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2018. PMID: 29664681. doi:10.1164/rccm.201706-1288OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。